Furthermore, our study primarily focuses on the expression of DLL3 and ASCL1 in small SCLC samples, which may not fully capture the heterogeneity of SCLC, especially in that most cases are inoperable or treated with different modalities. This evidence concerns the gene DLL3 and small cell lung carcinoma.